Skip to content
Logo Caladrius white logo
Logo Caladrius logo
  • Contact Us
Active Clinical Trials
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisors
  • Pipeline
    • Overview
    • Coronary Microvascular Dysfunction (CMD) XOWNA®
    • Critical Limb Ischemia (CLI) CLBS12 (HONEDRA® in Japan)
    • Diabetic Kidney Disease (DKD) CLBS201
    • No-Option Refractory Disabling Angina (NORDA) CLBS14 (OLOGO™ in the USA)
  • Research & Technology
    • Overview
    • CD34+ Cell Technology
    • Publications
  • Investors & News
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
      • Media Coverage
    • Financial & Filings
      • Quarterly Results
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Look Up
      • Analyst Coverage
    • Corporate Governance
      • Docs & Charters
      • Management Team
      • Board of Directors
    • Investor Resources
      • Investors FAQs
      • Email Alerts
      • IR Contact
      • Disclosures
  • Patients & Families
    • Overview
    • Coronary Microvascular Dysfunction Symptoms & Treatment
    • Critical Limb Ischemia and Buerger’s Disease Symptoms & Treatment
  • Careers
    • Overview
    • Job Opportunities
blue cell background
Home / About / Management Team

Management Team

David J. Mazzo, PhD
David J. Mazzo, PhD
President and Chief Executive Officer
  • Read Bio
Kristen K. Buck, MD
Kristen K. Buck, MD
Executive Vice President of R&D and Chief Medical Officer
  • Read Bio
Gregory S. Berkin
Gregory S. Berkin
Chief Information Officer
  • Read Bio
John D. Menditto
John D. Menditto
Vice President, Investor Relations and Corporate Communications
  • Read Bio
Gail Holler
Gail Holler
Vice President, Human Resources
  • Read Bio
James Nisco
James Nisco
Vice President, Finance and Treasury
  • Read Bio
Logo Caladrius white logo
Logo Caladrius logo
Active Clinical Trials
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisors
  • Pipeline
    • Overview
    • Coronary Microvascular Dysfunction (CMD) XOWNA®
    • Critical Limb Ischemia (CLI) CLBS12 (HONEDRA® in Japan)
    • Diabetic Kidney Disease (DKD) CLBS201
    • No-Option Refractory Disabling Angina (NORDA) CLBS14 (OLOGO™ in the USA)
  • Research & Technology
    • Overview
    • CD34+ Cell Technology
    • Publications
  • Careers
    • Overview
    • Job Opportunities
  • Investors & News
    • Overview
    • Press Releases
    • Corporate Presentation
    • Stock Information
    • Analyst Coverage
    • SEC Filings
    • FAQs
  • Facebook
  • Twitter
  • LinkedIn
Join Our Email List

110 Allen Road, 2nd Flr, Basking Ridge, NJ 07920|Telephone 908.842.0100

© 2022 Caladrius Biosciences, Inc. All rights reserved.
  • Site Map
  • Privacy Policy

110 Allen Road, 2nd Flr, Basking Ridge, NJ 07920|Telephone 908.842.0100

Caladrius Biosciences and Cend Therapeutics Announce Definitive Merger Agreement

Press Release Announcement

Click here for S-4 filing

Cend Therapeutics Website